
Greg L Beilhartz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6292124/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms. Journal of Biological Chemistry, 2008, 283, 22222-22232.	1.6	78
2	bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA). Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5791-5800.	3.3	76
3	HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors. Viruses, 2010, 2, 900-926.	1.5	74
4	Small Molecule Inhibitors of Clostridium difficile Toxin B-Induced Cellular Damage. Chemistry and Biology, 2015, 22, 175-185.	6.2	66
5	Translocation domain mutations affecting cellular toxicity identify the <i>Clostridium difficile</i> toxin B pore. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3721-3726.	3.3	63
6	Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFI®B in differentiating NB4 leukemia cells. Experimental Cell Research, 2010, 316, 1101-1108.	1.2	62
7	HIV-1 Reverse Transcriptase Can Simultaneously Engage Its DNA/RNA Substrate at Both DNA Polymerase and RNase H Active Sites: Implications for RNase H Inhibition. Journal of Molecular Biology, 2009, 388, 462-474.	2.0	56
8	Structure-Activity Analysis of Vinylogous Urea Inhibitors of Human Immunodeficiency Virus-Encoded Ribonuclease H. Antimicrobial Agents and Chemotherapy, 2010, 54, 3913-3921.	1.4	44
9	Efficient Delivery of Structurally Diverse Protein Cargo into Mammalian Cells by a Bacterial Toxin. Molecular Pharmaceutics, 2015, 12, 2962-2971.	2.3	40
10	Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota. Nature Communications, 2018, 9, 5233.	5.8	40
11	Repurposing bacterial toxins for intracellular delivery of therapeutic proteins. Biochemical Pharmacology, 2017, 142, 13-20.	2.0	39
12	Recognition of Semaphorin Proteins by P.Âsordellii Lethal Toxin Reveals Principles of Receptor Specificity in Clostridial Toxins. Cell, 2020, 182, 345-356.e16.	13.5	29
13	N348I in HIV-1 Reverse Transcriptase Can Counteract the Nevirapine-mediated Bias toward RNase H Cleavage during Plus-strand Initiation. Journal of Biological Chemistry, 2010, 285, 26966-26975.	1.6	28
14	Inhibition of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase by GSK5750 Correlates with Slow Enzyme-Inhibitor Dissociation. Journal of Biological Chemistry, 2014, 289, 16270-16277.	1.6	26
15	An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16938-16948.	3.3	26
16	Intracellular Delivery of Human Purine Nucleoside Phosphorylase by Engineered Diphtheria Toxin Rescues Function in Target Cells. Molecular Pharmaceutics, 2018, 15, 5217-5226.	2.3	16
17	Comment on "A small-molecule antivirulence agent for treating <i>Clostridium difficile</i> infection― Science Translational Medicine, 2016, 8, 370tc2.	5.8	15
18	Attenuated diphtheria toxin mediates siRNA delivery. Science Advances, 2020, 6, .	4.7	15

Greg L Beilhartz

#	Article	IF	CITATIONS
19	Derivatives of Mesoxalic Acid Block Translocation of HIV-1 Reverse Transcriptase. Journal of Biological Chemistry, 2015, 290, 1474-1484.	1.6	14
20	Small Molecules Take A Big Step Against Clostridium difficile. Trends in Microbiology, 2015, 23, 746-748.	3.5	6
21	Exploiting the diphtheria toxin internalization receptor enhances delivery of proteins to lysosomes for enzyme replacement therapy. Science Advances, 2020, 6, .	4.7	6
22	Telbivudine Exerts no Antiviral Activity against HIV-1 <i>In Vitro</i> and in Humans. Antiviral Therapy, 2011, 16, 1123-1130.	0.6	3